Is red light therapy an appropriate adjunctive treatment for mild musculoskeletal pain, superficial wound healing, or skin rejuvenation in otherwise healthy adults?

Red Light Therapy for Musculoskeletal Pain, Wound Healing, and Skin Rejuvenation

Red light therapy is not recommended as a standard treatment for mild musculoskeletal pain or superficial wound healing in otherwise healthy adults, as high-quality guidelines show it provides no benefit for complete wound healing despite reducing wound size, and better-established treatments exist. However, red light photodynamic therapy (PDT) has specific, guideline-supported applications for certain dermatologic conditions when used with photosensitizing agents.

For Musculoskeletal Pain

Do not use red light therapy for acute musculoskeletal injuries. The most recent ACP/AAFP guideline 1 from 2020 makes no mention of light therapy for acute musculoskeletal pain management, instead providing a clear treatment hierarchy:

• First-line: Topical NSAIDs with or without menthol gel (strong recommendation)
• Second-line options: Oral NSAIDs, acetaminophen, acupressure, or TENS
• Avoid: Opioids including tramadol

While one 2022 research review 2 suggests photobiomodulation may reduce pain in various musculoskeletal conditions, this contradicts the absence of light therapy in evidence-based guidelines. The ACP guideline for chronic low back pain 3 similarly excludes light therapy from recommended treatments, instead prioritizing exercise, multidisciplinary rehabilitation, and acupuncture.

Clinical caveat: The research evidence for photobiomodulation in musculoskeletal pain is of insufficient quality to override guideline recommendations that are based on systematic reviews of higher-quality trials.

For Superficial Wound Healing

Red light therapy should not be used for routine wound healing. The 2015 ACP guideline on pressure ulcers 4 found that while light therapy reduced ulcer size compared to control, it was equivalent to sham treatment for complete wound healing—the outcome that actually matters for patient morbidity. The guideline notes no substantial adverse events but makes no recommendation for its use.

The 2024 IWGDF diabetes foot ulcer guideline 5 does not include light therapy among recommended interventions, instead focusing on:

• Standard wound care with appropriate dressings
• Negative pressure wound therapy only for post-surgical wounds (not routine ulcers)
• Specific biological agents in limited circumstances

Key distinction: Reducing wound size is not the same as achieving complete healing. Light therapy may make wounds appear smaller without actually closing them, which does not reduce infection risk or improve patient outcomes.

Recent research studies 6, 7 show some promise for LED therapy in wound healing, but these are small studies that have not been incorporated into clinical practice guidelines. The 2024 study 7 showing upregulation of collagen and VEGF is preliminary animal research that requires validation in rigorous human trials before clinical application.

For Skin Rejuvenation

Red light therapy may be considered for cosmetic skin rejuvenation, though this falls outside medical necessity. Recent research 8, 9 demonstrates that LED photobiomodulation at 630 nm can improve wrinkles, skin elasticity, and overall skin quality when used 2-3 times weekly for 8-12 weeks. The 2025 study 8 showed significant improvement in crow's feet with 630 nm LED combined with 850 nm infrared over 16 weeks.

Important context: These are cosmetic outcomes, not medical treatments affecting morbidity or mortality. The studies show improvements in appearance-related measures but do not address quality of life in the medical sense.

Photodynamic Therapy (PDT) - The Exception

Red light PDT with photosensitizing agents (ALA or MAL) is guideline-supported for specific dermatologic conditions 10, 11, 10, 12:

Recommended uses:

• Actinic keratosis: Offer PDT for cosmetically sensitive sites, multiple lesions, or large areas (strong recommendation) 10
• Superficial basal cell carcinoma: Offer PDT, particularly for poorly healing sites or cosmetically sensitive areas (strong recommendation) 10
• Squamous cell carcinoma in situ (Bowen's disease): Offer PDT for poorly healing sites, multiple lesions, or large areas 10, 12. The 2007 guideline 12 notes 88% initial clearance and 82% 12-month clearance rates, superior to 5-FU

Critical distinction:

This is not simple red light therapy—it requires:

• Application of photosensitizing agent (20% ALA or MAL) for 3-6 hours
• Specific red light wavelength (630 nm) at defined doses
• Medical supervision and proper patient selection
• Understanding that pain during treatment is common

Do not use for nodular BCC at high-risk sites or invasive squamous cell carcinoma 10.

Bottom Line Algorithm

For mild musculoskeletal pain:

1. Use topical NSAIDs ± menthol (first-line)
2. Consider oral NSAIDs or acetaminophen
3. Do not use red light therapy

For superficial wounds in healthy adults:

1. Use standard wound care with hydrocolloid or foam dressings
2. Ensure adequate protein nutrition
3. Do not use red light therapy as it doesn't improve complete healing

For cosmetic skin concerns:

• Red light therapy may be used but is elective/cosmetic, not medically necessary
• Requires 8-16 weeks of consistent use (2-3x weekly) for visible results

For specific skin lesions (AK, superficial BCC, Bowen's disease):

• Refer to dermatology for photodynamic therapy evaluation
• This requires photosensitizing agents, not standalone light therapy